TomaLab
  • CHI SIAMO
    • Mission
    • Codice etico
    • Qualità
    • Amministrazione Trasparente
    • Carta Servizi
  • PAZIENTI
    • Riproduzione e infertilità
    • Oncologia
    • Cardiologia
    • Oftalmologia
  • SPECIALISTI
    • Riproduzione e infertilità
    • Genetica oncologica
    • Anatomia patologica
    • Genetica cardiologica
    • Genetica oftalmologica
    • Genetica forense
    • Malattie rare
  • ISTITUZIONI
  • ESAMI
  • GENET
  • NOTIZIE
    • Articoli
    • Webinar
    • Pubblicazioni
    • LinkedIn
  • CONTATTI
  • SCARICA REFERTI
Seleziona una pagina

BACs-on-Beads™ (BoBs™) Assay for the Genetic Evaluation of Prenatal Samples and Products of Conception

Ago 1, 2016

Il laboratorio TOMA pubblica un capitolo di un libro in collaborazione con il Prof François Vialard (Francia) e la Professoressa Susan Gross (New York, USA). Esso si concentra sulla descrizione dettagliata e sulle specifiche della metodica Bacs-on-Beads per la rilevazione di sbilanciamenti patogenetici in diagnosi prenatale e su tessuti abortivi. Il lavoro è stato pubblicato su Methods in Molecular Biology.
Grati FR1, Vialard F, Gross S.
1Research and Development, Cytogenetics and Molecular Biology, TOMA Advanced Biomedical Assays, S.p.A., Via Francesco Ferrer 25/27, 21052, Busto Arsizio, VA, Italy, fgrati@tomalab.com.
Methods Mol Biol. 2015;1227:259-78. doi: 10.1007/978-1-4939-1652-8_13.

BACs-on-Beads™ (BoBs™) is a new emerging technology, a modification of comparative genomic hybridization that can be used to detect DNA copy number gains and losses. Here, we describe the application of two different types of BoBs™ assays: (1) Prenatal BoBs (CE-IVD) to detect the most frequent syndromes associated with chromosome microdeletions, as well as the trisomy 13, 18 and 21, and (2) KaryoLite BoBs (RUO) which can detect aneuploidy in all chromosomes by quantifying proximal and terminal regions of each chromosomal arm. The interpretation of the results by BoBsoft™ software is also described. Although BoBs™ may not have the breadth and scope to replace chromosomal microarrays (array comparative genomic hybridization and single nucleotide polymorphism array) in the prenatal setting, particularly when a fetal anomaly has been detected, it is a well suited alternative for FISH or QF-PCR because BoBs™ is comparable, if not superior in terms of cost, turnaround time (TAT) and throughput and accuracy. BoBs™ also has the ability to detect significant fetal mosaicism (≥30% with Prenatal BoBs and ≥50% with KaryoLite BoBs). However, perhaps the greatest strength of this new technology is the fact that unlike FISH or QF-PCR, it has the ability to detect common microdeletion syndromes or additional aneuploidies, both of which may be easily missed despite excellent prenatal sonography. Thus, when BoBs™ is applied in the correct clinical setting and run and analyzed in appropriate laboratories this technique can improve and augment best practices with a personalization of prenatal care.

Clicca qui per l’articolo completo
 

Meta

  • Accedi
  • Feed dei contenuti
  • Feed dei commenti
  • WordPress.org
Toma Lab logo

TOMA Advanced Biomedical Assays S.p.A.
Società Unipersonale
Via Francesco Ferrer, 25/27 – 21052 Busto Arsizio (VA)
Capitale Soc. 2.050.000€ i.v.
Codice univoco: W7YVJK9
REA CCIAA Varese 155894
C.F. Reg. Impr. e P.IVA 00772010120
Soggetta a direzione e coordinamento di Impact Lab S.p.A.

Contatti
Tel: 0331.652911
Fax: 0331.652919

 
   

Copyright 2020 TomaLab Advanced Biomedical Assays | Powered by Prochemi | Privacy Policy | Cookie Policy | Carta dei servizi